Pharsight

1. List of Bylvay drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7132416	ALBIREO	Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia	Sep, 2022 (8 months ago)
US10975046	ALBIREO	Crystal modifications of odevixibat	Jun, 2039 (16 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10487111	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US10981952	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US9694018	ALBIREO	IBAT inhibitors for the treatment of liver disease	Nov, 2031 (8 years from now)
US10011633	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US10093697	ALBIREO	IBAT inhibitors for the treatment of liver diseases	Nov, 2031 (8 years from now)
US11365182	ALBIREO	Crystal modifications of odevixibat	Jun, 2039 (16 years from now)
US11583539	ALBIREO	Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors	Nov, 2041 (18 years from now)

Do you want to check out BYLVAY patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jul 20, 2026
Orphan Drug Exclusivity (ODE)	Jul 20, 2028

NCE-1 date: 2025-07-20

Market Authorisation Date: 20 July, 2021

Treatment: Method of reducing serum bile acids in patients 3 months or older suffering from progressive familial intrahepatic cholestasis (pfic); Method of treating pruritus in patients 3 months or older sufferi...

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL